an intravenous glipizide ( 2 mg ) test was carried out in 7 patients before and after a period of associated insulin-glipizide treatment ( mean daily dose of 80.7 i.v . lente insulin and 14.3 mg glipizide for 9.1 months ) to assess the capacity of the sulphonylurea to reduce acutely the plasma glucose and lactate levels .
C0017642
glipizide
C0038766
sulphonylurea